Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care
FOR REFERENCE ONLY
Release Date: March 23, 2015
Expiration Date: March 24, 2016
ESTIMATED TIME TO COMPLETE ACTIVITY:
This activity has been designed to meet the educational needs of Medical Oncologists involved in the care of patients with non-small cell lung cancer (NSCLC).
Upon completion of this program, participants should be better able to:
- Apply appropriate biomarker testing when treating advanced NSCLC patients based on current evidence
- Develop a treatment plan for NSCLC patients that incorporates biomarker and molecular testing results
- Educate patients on targeted therapy agents currently in clinical trials
- Select appropriate patients for clinical trials of targeted therapies for treatment of NSCLC
- Define the process of immune surveillance
- Describe the role of immune checkpoint inhibitors such as the PD-1 (programmed cell death-1) antibodies in NSCLC
- Educate patients on immunotherapy agents being investigated
- Select appropriate patients for clinical trials of immunotherapies for treatment of NSCLC
- Identify three immune-related adverse events (irAEs) experienced by NSCLC patients receiving immunotherapy
- Describe management strategies for common irAEs experienced by patients with NSCLC receiving immunotherapy
Corey Langer, MD
Abramson Cancer Center, University of Pennsylvania
Heather Wakelee, MD
Stanford Cancer Institute
Naiyer A. Rizvi, MD
Memorial Sloan Kettering/Weill Cornell Medical College
Julie Renee Brahmer, MD
Sidney Kimmel Comprehensive Cancer Center
Matthew M. Burke, MBA, RN, MSN, APRN-BC
Smilow Cancer Hospital at Yale-New Haven
PHYSICIAN CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Carevive Systems, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Corey Langer, MD||Grant/Research Support, Bristol Myers Squibb, Pfizer, Eli Lilly and Company, Genentech Inc., OSI (Astelas), Merck & Co., GlaxoSmithKline, Nektar Therapeutics; Scientific Advisor, Bristol- Myers Squibb, ImClone Systems, Sanofi US, Pfizer, Inc., Eli Lilly and Company, Amgen, AstraZeneca, Novartis, Genentech, Inc., Bayer, Onyx Pharmaceuticals, Inc., Abraxis, Abbott Laboratories, Morphotek, Inc., Biodesix, Inc., Clarient, Inc., Caris Dx, Vertex Pharmaceuticals, Synta Pharmaceuticals, Celgene Corporation, Boehringer-Ingelheim; Speakers’ Bureaus, Eli Lilly and Company, Genentech, Inc., OSI, Imclone-BMS (all curtailed as of 12/10); Data and Safety Monitoring Committee, Eli Lilly and Company, Amgen, Synta Pharmaceuticals, Agennix.|
|Heather Wakelee, MD||Consulting fees, Peregrine Parmaceuticals, Inc.; Contracted Research, Genentech, Inc., Roche Pharmaceuticals, Celgene Corporation, Eli Lilly and Company, Pfizer, Inc., Novartis, Clovis Oncology, AstraZeneca, Exelixis, Inc., Regeneron Pharmaceuticals, Inc., Xcovery, Bristol-Myers Squibb.|
|Naiyer A. Rizvi, MD||Consulting fees, Merck & Co., Bristol-Myers Squibb, AstraZeneca, MedImmune, LLC, Genentech, Inc. Julie Renee Brahmer, MD, reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Consulting fees, Merck & Co., Bristol-Myers Squibb, Eli Lilly and Company, Celgene Corporation; Contracted Research, Bristol-Myers Squibb, MedImmune, AstraZeneca, Merck & Co.|
|Julie Renee Brahmer, MD||Consulting fees, Merck & Co., Bristol-Myers Squibb, Eli Lilly and Company, Celgene Corporation; Contracted Research, Bristol-Myers Squibb, MedImmune, AstraZeneca, Merck & Co.|
|Matthew M. Burke, MBA, RN, MSN, APRN-BC||Consulting fees, Pfizer, Inc.; Speakers’ Bureaus, Bristol-Myers Squibb, Genentech, Inc., ION Solutions.|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following Carevive Systems, Inc (formerly On Q Health, Inc.) planners and managers reported the following: Timothy J. DiChiara, PhD, Consulting Fees, Gilead Sciences; Karen Hammelef, DNP, RN, Speakers’ Bureau, Novartis Pharmaceuticals Corporation.
INSTRUCTIONS FOR PARTICIPATION AND CREDIT
There are no fees for participating and receiving CME credit for this activity. During the period March 23, 2015 through March 23, 2016 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 10289. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.
HARDWARE AND SOFTWARE REQUIREMENTS
CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.